

**Table S1: Univariate analysis of variables associated with significant liver fibrosis in 88 adolescent patients with CHB**

Index	Patients with mild liver fibrosis (n=45)	Patients with significant liver fibrosis (n=43)	Univariate analysis P value
Age (years)	8.97±5.37	8.99±5.93	0.985
Gender male	32(71.1%)	25(58.1%)	0.203
female	13(28.9%)	18(41.9%)	
ALT(IU/L)	122.40±153.57	187.88±192.95	0.081
AST(IU/L)	83.71±61.60	130.26±109.04	0.017
AST/ALT	0.97±0.53	0.86±0.48	0.295
TBIL(umol/L)	9.68±5.30	9.40±4.70	0.791
CHE*(U/L)	7572.13±1281.39	7074.70±1289.61	0.073
PLT(×10 <sup>9</sup> /L)	255.38±70.51	227.28±57.74	0.044
PTA* (%)	101±17	93±13	0.021
ALB (g/U)	42.25±4.8	40.53±2.37	0.036
Log10(HBV DNA)	7.83±0.88	7.48±1.08	0.102
APRI	0.86±0.58	1.39±0.95	0.002

**Note: PTA: Prothrombin time activity; CHE: cholinesterase.**

**Table S2: Univariate analysis of variables associated with significant liver inflammation in 88 adolescent patients with CHB**

Index	Patients with mild liver inflammation (n=31)	Patients with significant liver inflammation (n=57)	Univariate analysis P value
Age (years)	7.98 ± 4.42	9.14 ± 5.28	0.299
Sex male	24(77.4%)	33(57.9%)	0.067
female	7(22.6%)	24(42.1%)	
ALT(IU/L)	95.61 ± 83.87	186.37 ± 203.50	0.004
AST(IU/L)	73.26 ± 37.06	124.51 ± 105.23	0.001
AST/ALT	1.01 ± 0.53	0.87 ± 0.49	0.217
TBIL(umol/L)	9.50 ± 4.79	9.63 ± 5.41	0.908
CHE(U/L)	8073.74 ± 1262.96	6924.07 ± 1142.87	0.000
PLT(×10 <sup>9</sup> /L)	263.87 ± 70.17	229.75 ± 60.71	0.019
PTA (%)	100 ± 15	95 ± 15	0.189
ALB(g/U)	42.75 ± 5.04	40.68 ± 2.89	0.041
Log <sub>10</sub> (HBV DNA)	7.87 ± 0.90	7.55 ± 1.03	0.145
APRI	0.75 ± 0.46	1.32 ± 0.90	0.000